利用囊壳再循环抑制剂联合治疗慢性乙型肝炎

arXiv - QuanBio - Cell Behavior Pub Date : 2024-02-12 DOI:arxiv-2402.07701

Rupchand Sutradhar, D C Dalal

{"title":"利用囊壳再循环抑制剂联合治疗慢性乙型肝炎","authors":"Rupchand Sutradhar, D C Dalal","doi":"arxiv-2402.07701","DOIUrl":null,"url":null,"abstract":"In this paper, we investigate the dynamics of hepatitis B virus infection\ntaking into account the implementation of combination therapy through\nmathematical modeling. This model is established considering the interplay\nbetween uninfected cells, infected cells, capsids, and viruses. Three drugs are\nconsidered for specific roles (i) pegylated interferon (PEG IFN) for immune\nmodulation, (ii) lamivudine (LMV) as a reverse-transcriptase inhibitor, and\n(iii) entecavir (ETV) to block capsid recycling. Using these drugs, three\ncombination therapies are introduced, specifically CT PEG IFN plus LMV, CT PEG\nIFN plus ETV, and CT PEG IFN plus LMV plus ETV. As a result, when LMV is used\nin combination therapy with PEG IFN and ETV, the impacts of ETV become\ninsignificant. In conclusion, if the appropriate drug effectively inhibits\nreverse transcription, there is no need for an additional inhibitor to block\ncapsid recycling.","PeriodicalId":501321,"journal":{"name":"arXiv - QuanBio - Cell Behavior","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combination Therapy for Chronic Hepatitis B Using Capsid Recycling Inhibitor\",\"authors\":\"Rupchand Sutradhar, D C Dalal\",\"doi\":\"arxiv-2402.07701\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this paper, we investigate the dynamics of hepatitis B virus infection\\ntaking into account the implementation of combination therapy through\\nmathematical modeling. This model is established considering the interplay\\nbetween uninfected cells, infected cells, capsids, and viruses. Three drugs are\\nconsidered for specific roles (i) pegylated interferon (PEG IFN) for immune\\nmodulation, (ii) lamivudine (LMV) as a reverse-transcriptase inhibitor, and\\n(iii) entecavir (ETV) to block capsid recycling. Using these drugs, three\\ncombination therapies are introduced, specifically CT PEG IFN plus LMV, CT PEG\\nIFN plus ETV, and CT PEG IFN plus LMV plus ETV. As a result, when LMV is used\\nin combination therapy with PEG IFN and ETV, the impacts of ETV become\\ninsignificant. In conclusion, if the appropriate drug effectively inhibits\\nreverse transcription, there is no need for an additional inhibitor to block\\ncapsid recycling.\",\"PeriodicalId\":501321,\"journal\":{\"name\":\"arXiv - QuanBio - Cell Behavior\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"arXiv - QuanBio - Cell Behavior\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/arxiv-2402.07701\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"arXiv - QuanBio - Cell Behavior","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/arxiv-2402.07701","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在本文中，我们通过数学建模研究了乙型肝炎病毒感染的动力学，其中考虑到了联合疗法的实施。该模型的建立考虑了未感染细胞、感染细胞、囊壳和病毒之间的相互作用。该模型考虑了三种药物的特定作用：(i) 用于免疫调节的聚乙二醇干扰素 (PEG IFN)；(ii) 作为逆转录酶抑制剂的拉米夫定 (LMV)；(iii) 阻断病毒盖回收的恩替卡韦 (ETV)。利用这些药物，推出了三种组合疗法，即 CT PEG IFN 加 LMV、CT PEGIFN 加 ETV 和 CT PEG IFN 加 LMV 加 ETV。结果，当 LMV 与 PEG IFN 和 ETV 联合使用时，ETV 的影响变得显著。总之，如果适当的药物能有效抑制逆转录，就不需要额外的抑制剂来阻断capsid循环。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Combination Therapy for Chronic Hepatitis B Using Capsid Recycling Inhibitor

In this paper, we investigate the dynamics of hepatitis B virus infection taking into account the implementation of combination therapy through mathematical modeling. This model is established considering the interplay between uninfected cells, infected cells, capsids, and viruses. Three drugs are considered for specific roles (i) pegylated interferon (PEG IFN) for immune modulation, (ii) lamivudine (LMV) as a reverse-transcriptase inhibitor, and (iii) entecavir (ETV) to block capsid recycling. Using these drugs, three combination therapies are introduced, specifically CT PEG IFN plus LMV, CT PEG IFN plus ETV, and CT PEG IFN plus LMV plus ETV. As a result, when LMV is used in combination therapy with PEG IFN and ETV, the impacts of ETV become insignificant. In conclusion, if the appropriate drug effectively inhibits reverse transcription, there is no need for an additional inhibitor to block capsid recycling.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

arXiv - QuanBio - Cell Behavior

自引率

0.00%

发文量